Thymosin Beta-4 and Australia's Poisons Standard

A research-use summary of the scheduling context around Thymosin Beta-4 and what it means for laboratory work.

Australia’s June 2026 Poisons Standard lists Thymosin Beta-4 in Schedule 4 and Appendix D. Find the exact entries, official source and legal limits.

Australia’s June 2026 Poisons Standard marks Thymosin Beta-4 with a # in Schedule 4. The instrument states that substances marked # are also listed in Appendix D. Appendix D section 5 separately names both TB-500 and Thymosin Beta-4.

The Poisons Standard is a federal legislative instrument. It classifies scheduled substances and supplies a model that Australian states and territories implement through their own medicines and poisons laws. It is not a product approval register and it should not be read in isolation when determining whether a particular activity is authorised.

Where the Thymosin Beta-4 entries appear

What Schedule 4 and Appendix D mean

Schedule 4 is headed “Prescription only medicines and prescription animal remedies”. Appendix D identifies additional controls. In the 2026 instrument, section 5 is headed “Poisons for which possession without authority is illegal”. The applicable authority, exemptions, record requirements and supply rules depend on the facts and the legislation in the relevant state or territory.

A Research Use Only label is not a legal exemption

Labelling a product Research Use Only describes intended use. It does not, by itself, displace the Poisons Standard or state and territory controls. Anyone handling, possessing or supplying a scheduled substance should verify the current instrument and obtain advice specific to their jurisdiction and activity.

How to verify the current listing

Separate question: ARTG status

The Australian Register of Therapeutic Goods and the Poisons Standard answer different questions. A scheduling entry does not establish that a product is included in the ARTG. Confirm each status from its own official register rather than inferring one from the other.

Substance identity and analytical documentation

The scheduling entry and a material’s analytical identity are also separate questions. For the substance terminology and evidence limits, see the TB-500 and Thymosin Beta-4 research reference . The TB-500 10mg batch page publishes the matching analytical record. Neither page changes the legal effect of the current instrument.

This page provides general source-navigation information, not legal advice. The linked federal instrument is the primary source. For in vitro laboratory research purposes only. Not for human or animal consumption.

Links lead to the original paper, DOI record, or open-access full text where available.

Australian Research Peptide Regulations: What Labs Need to Know

This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. By purchasing, you confirm you are a qualified researcher or acting on behalf of a licensed research facility, and you assume full responsibility for the safe handling, storage, and lawful use of this compound.

Research Use Only. This article is for general laboratory research information and makes no therapeutic claim.
Keep reading

More from the journal